Price
30.4
-0.3%52W Range
Market Cap
₹9.29 Cr
Traded: ₹0.00 Cr (0.01%) 0.0x
Free Float: ₹2.53 Cr (0.03% of FF traded)
Volume · 60D trend
243 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | -- | +6.0% | +10.0% | -26.0% | -- | Stable |
| ROE | +2.0% | +5.0% | +4.0% | -- | -- | Stable |
| Sales | +9.0% | +5.0% | -54.0% | -- | -72.0% | Decelerating |
| Profit | +8.0% | +15.0% | -68.0% | -- | -96.0% | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 1 |
| OPM % | 50.0% | 0.0% | 20.0% | 0.0% | 33.3% | 0.0% | 72.7% | 66.7% | 81.3% | -- | 50.0% | 28.6% | 50.0% | 93.0% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 1 |
| Tax % | 0.0% | -- | 0.0% | -- | 0.0% | -- | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 1 |
| Exceptional Items | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 0.0 | -0.0 | 0.0 | 0.0 | 0.1 | -0.3 | 0.5 | 0.5 | 0.4 | -0.1 | 0.1 | 0.1 | 0.1 | 3.2 |
| Sales Growth (YoY) | -56.0% | -85.0% | -77.0% | -57.0% | -44.0% | -- | 450.0% | 200.0% | 167.0% | -100.0% | -94.0% | 250.0% | -94.0% | -- |
| Sales Growth (QoQ) | -- | -20.0% | -44.4% | 0.0% | -65.4% | 18.2% | 4.8% | 31.3% | -- | -100.0% | -42.9% | 16.7% | -94.0% | -- |
| OP Growth (YoY) | -33.3% | -- | -93.8% | -100.0% | -76.9% | 100.0% | 700.0% | 600.0% | 333.3% | -104.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | -- | -100.0% | -- | -100.0% | -- | -100.0% | 14.3% | 7.7% | 425.0% | -300.0% | 0.0% | -33.3% | -96.8% | -- |
| Profit Growth (YoY) | -50.0% | 88.0% | -94.0% | -100.0% | -85.0% | -100.0% | 700.0% | 650.0% | 333.0% | -104.0% | -60.0% | 167.0% | 160.0% | 465.0% |
| EPS Growth (YoY) | -- | 88.5% | -94.2% | -100.0% | -83.7% | -100.0% | 642.9% | 600.0% | 330.0% | -104.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -200.0% | -- | -100.0% | 126.9% | -150.0% | 6.1% | 13.9% | 430.8% | -285.7% | 0.0% | -30.0% | -96.9% | -- |
| OP Margin | -- | 0.0% | 20.0% | 0.0% | 33.3% | 0.0% | 72.7% | 66.7% | 81.3% | -- | 50.0% | 28.6% | 50.0% | 93.0% |
| Net Margin | -- | -25.0% | 20.0% | 0.0% | 22.2% | -30.8% | 72.7% | 71.4% | 81.3% | -- | 50.0% | 28.6% | 50.0% | 98.0% |
| Material Cost % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 80.8% | 0.0% | 0.0% | 0.0% | -- | 0.0% | 0.0% | 0.0% | 0.0% |
| Employee Cost % | 25.0% | 0.0% | 40.0% | 44.4% | 44.4% | 15.4% | 13.6% | 19.1% | 6.3% | -- | 0.0% | 14.3% | 33.3% | 3.0% |
| P/S | 42.23 | 34.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 1013.33 | 434.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.37 | 2.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed herewith unaudited financial results for the quarter ended on 30th June, 2026.
Unaudited financial results for Quarter ended on 30 June 2026.
Considered and approved the standalone Un-audited financial results of the company for the quarter ended on 30th June 2026.
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve unaudited financial ....
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on 30th June, 2026.
Closure of trading window.
Please find enclosed herewith audited financial results for the quarter and year ended on 31 March 2026.
Appointment of Mr. Navjyoti Kumar Jha as internal auditor of the company for the F.Y. 2026-27.
Standalone audited financial results of the company for the quarter and year ended on 31 March 2026.
1. Considered and approved the standalone audited financial results of the company for the quarter and financial year ended 31st March 2026; 2. Considered and approved the appointment ....
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited financial ....
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on 31st March, 2026.
Disclosure made by Promoters and Promoters group of the company under Regulation 31(4) of SEBI (substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ....
Disclosure made by Promoters and Promoters group of the company under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ....
Closure of Trading Window for the quarter and year ending on March 31, 2026.
Please find enclosed herewith unaudited financial results for the quarter and nine months ended on 31st December 2025.
Please find enclosed herewith the financial results for the Quarter and Nine Months ended 31st December 2025, pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) ....
Cessation of Mr. Ashok Kumar (DIN: 07647876) from the directorship of the company.
Please find enclosed herewith the Outcome of the Board Meeting dated 15/01/2026 for your reference.
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on 31st December, 2025.
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/01/2026 ,inter alia, to consider and approve the unaudited financial ....
Submission of voting results of 31st Annual General Meeting of the Company under Regulation 44(3) of the SEBI (listing Obligations & Disclosure Requirements) Regulations, 2015.
Please find enclosed herewith copy of proceeding of 31st Annual General Meeting of the company for your reference.
Please find enclosed herewith intimation of closure of trading window.
Please find enclosed herewith Newspaper intimation for the 31st Annual General Meeting for your reference.
Compliance Under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Annual Report for The Financial Year 2024-25
Please find enclosed herewith the Notice of the Annual General Meeting for your reference.
Please find enclosed herewith book closure intimation for your reference.
Please Find enclosed herewith the Outcome of the Board Meeting dated 08/12/2025 for your reference.
Please find enclosed herewith un-audiited financial results for the quarter and half year ended on 30th September 2025.
Please find enclosed herewith Outcome of Board Meeting Pursuant to regulation 30 of Sebi (LODR)Regulation ,2015 held on today i.e. 15th October 2025
Please find enclosed herewith unaudited standalone financial results for the Quarter and half Yearly ended on September 30th, 2025.
Certificate under Regulation 74 (5) of SEBI (DP) Regulation, 2018 for the quarter ended on 30th September, 2025.
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/10/2025 ,inter alia, to consider and approve The unaudited financial ....
Please find enclosed herewith Intimation for closure of trading window.
Intimation of Approval of Extension of time for holding Annual General Meeting (AGM) of the Company for the Financial Year ended on 31st March 2025, pursuant to Regulation 30 of SEBI (Listing ....
Newspaper Advertisement regarding publication of unaudited financial result of the company for the quarter ended 30 June, 2025.
Re-appointment of Mr. Yogesh Agrawal as Chairman & Managing Director of the Company for the period of five (5) years with effect from 07.09.2025.
Considered and approved the appointment of Mr. Navjyoti Kumar Jha as internal auditor of the company for the FY 2025-26.
Appointment of M/s SBR & Co. LLP, Company Secretaries (LLP No. AA0-9057) as Secretarial auditors of the company for the FY 2025-2030.
Considered and approve the unaudited financial results for the quarter ended June 30, 2025 along with limited review report.
1. Considered and approved the Un-audited financial results of the company for the quarter ended 30th June 2025. 2. Appointment of M/s. SBR & Co. LLP, Company Secretaries (LLP No. AAO-9057) ....
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve the unaudited financial ....
Certificate under Regulation 74 (5) of SEBI (DP) Regulation, 2018 for the quarter ended on 30th June, 2025.
Please find enclosed herewith Intimation for closure of trading window.
Financial results for Quarter and Financial Year ended on 31 March 2025.
Newspaper Advertisement regarding publication of Financial Results for the quarter and year ended March 31, 2025.
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve the audited financial ....
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on 31st March 2025.
Please find enclosed herewith the Newspaper Advertisement Regarding Publications Standalone Un-Audited Financial results of the Company for the Quarter and Nine Months ended 31st December 2024